<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346967</url>
  </required_header>
  <id_info>
    <org_study_id>VinmecRISCGT72</org_study_id>
    <nct_id>NCT03346967</nct_id>
  </id_info>
  <brief_title>Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency</brief_title>
  <acronym>MSCSHD</acronym>
  <official_title>Evaluation of Autologous Adipose Derived Mesenchymal Stem Cells (AD-MSCs) Therapy on Sexual Hormone Deficiency in the Middle-aged Patients: an Open-label, Single-group Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Research Institute of Stem Cell and Gene Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Research Institute of Stem Cell and Gene Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of adipose derived
      mesenchymal stem cells (AD-MSCs) therapy on sexual hormone deficiency in the middle-aged
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficiency of adipose-derived
      mesenchymal stem cells in 30 patients with sexual hormone deficiency at Vinmec International
      Hospital, Hanoi, Vietnam
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>30 patients with sexual hormone deficiency will be injected AD-MSCs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Comparison between Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male at pre and post AD-MSCs therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Stem cell Administration for female patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cell Administration for male patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>adipose-derived mesenchymal stem cells</intervention_name>
    <description>Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure</description>
    <arm_group_label>Stem cell Administration for female patients</arm_group_label>
    <arm_group_label>Stem cell Administration for male patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 40 years to 65 years (Male) and from 40 years to menopause age (Female)

          -  Male: decrease in libido, decrease in intercourse frequency, erectile dysfunction,
             Difficulty in concentration, testosterone level ≤ 12 nMol/dL

          -  Female: reduced or absent menstruation after radiation exposure or chemotherapy; Hot
             flushes, excessive sweating, and anxiety, together with other symptoms associated with
             the menopause, AMH level ≤ 2 ng/ml and/or FSH level ≥ 10 mIU/ml.

          -  Patients signed the informed consent form

        Exclusion Criteria:

          -  Surgery removal of endocrine glands

          -  Abnormalities in the endrocrine glands

          -  Hormone deficiency due to diabetes and other metabolic disorders

          -  Active autoimmune diseases

          -  Current usage of immunosuppressive drugs

          -  Coagulation disorders

          -  Allergy to anesthetic agents

          -  Severe health conditions such as cancer, failure of heart, lung, liver or kidney

          -  Active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>40 years to 65 years (Male) and from 40 years to menopause age (Female)
Male: decrease in libido, decrease in intercourse frequency, erectile dysfunction, Difficulty in concentration, testosterone level ≤ 12 nMol/dL
Female: reduced or absent menstruation after radiation exposure or chemotherapy; Hot flushes, excessive sweating, and anxiety, together with other symptoms associated with the menopause, AMH level ≤ 2 ng/ml and/or FSH level ≥ 10 mIU/ml.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liem Nguyen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinmec Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liem Nguyen, PhD</last_name>
    <phone>(+84 4) 3 974 3556</phone>
    <phone_ext>1420</phone_ext>
    <email>v.liemnt@vinmec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phuong Nguyen, MPH</last_name>
    <phone>(+84) 914740683</phone>
    <email>hoangphuonghsph@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vinmec Research Institute of Stem Cell and Gene Technology</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Nguyen, MPH</last_name>
      <phone>(+84)914740683</phone>
      <email>hoangphuonghsph@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Liem Nguyen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Reed-Maldonado AB, Lue TF. The Current Status of Stem-Cell Therapy in Erectile Dysfunction: A Review. World J Mens Health. 2016 Dec;34(3):155-164. doi: 10.5534/wjmh.2016.34.3.155. Epub 2016 Dec 22. Review.</citation>
    <PMID>28053944</PMID>
  </results_reference>
  <results_reference>
    <citation>Haahr MK, Jensen CH, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, Lund L, Sheikh SP. Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. EBioMedicine. 2016 Jan 19;5:204-10. doi: 10.1016/j.ebiom.2016.01.024. eCollection 2016 Mar.</citation>
    <PMID>27077129</PMID>
  </results_reference>
  <results_reference>
    <citation>Charles-de-Sá L, Gontijo-de-Amorim NF, Maeda Takiya C, Borojevic R, Benati D, Bernardi P, Sbarbati A, Rigotti G. Antiaging treatment of the facial skin by fat graft and adipose-derived stem cells. Plast Reconstr Surg. 2015 Apr;135(4):999-1009. doi: 10.1097/PRS.0000000000001123.</citation>
    <PMID>25811565</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AD mesenchymal stem cells;sexual hormone deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

